Myriad Genetics Inc SEC filings MYGN
Myriad Genetics Inc has 1,002 filings in SEC EDGAR's recent list, going back to Aug 14, 2015. Its latest annual report, Form ARS, was filed on Apr 14, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Jul 31, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Nov 5, 2026 (other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Jul 31, 2026 | Jun 30, 2026 |
| 10-Q | Quarterly report | May 6, 2026 | Mar 31, 2026 |
| 10-Q | Quarterly report | Nov 4, 2025 | Sep 30, 2025 |
| 10-Q | Quarterly report | Aug 6, 2025 | Jun 30, 2025 |
| 10-Q | Quarterly report | May 7, 2025 | Mar 31, 2025 |
| 10-Q | Quarterly report | Nov 8, 2024 | Sep 30, 2024 |
| 10-Q | Quarterly report | Aug 7, 2024 | Jun 30, 2024 |
| 10-Q | Quarterly report | May 8, 2024 | Mar 31, 2024 |
| 10-Q | Quarterly report | Nov 7, 2023 | Sep 30, 2023 |
| 10-Q | Quarterly report | Aug 4, 2023 | Jun 30, 2023 |
| 10-Q | Quarterly report | May 4, 2023 | Mar 31, 2023 |
| 10-Q | Quarterly report | Nov 2, 2022 | Sep 30, 2022 |
| 10-Q | Quarterly report | Aug 5, 2022 | Jun 30, 2022 |
| 10-Q | Quarterly report | May 6, 2022 | Mar 31, 2022 |
| 10-Q | Quarterly report | Nov 4, 2021 | Sep 30, 2021 |
| 10-Q | Quarterly report | Aug 4, 2021 | Jun 30, 2021 |
| 10-Q | Quarterly report | May 5, 2021 | Mar 31, 2021 |
| 10-Q | Quarterly report | Nov 9, 2020 | Sep 30, 2020 |
| 10-Q | Quarterly report | May 6, 2020 | Mar 31, 2020 |
| 10-Q | Quarterly report | Feb 7, 2020 | Dec 31, 2019 |
| 10-Q | Quarterly report | Nov 6, 2019 | Sep 30, 2019 |
| 10-Q | Quarterly report | May 8, 2019 | Mar 31, 2019 |
| 10-Q | Quarterly report | Feb 6, 2019 | Dec 31, 2018 |
| 10-Q | Quarterly report | Nov 7, 2018 | Sep 30, 2018 |
| 10-Q | Quarterly report | May 9, 2018 | Mar 31, 2018 |
| 10-Q | Quarterly report | Feb 7, 2018 | Dec 31, 2017 |
| 10-Q | Quarterly report | Nov 8, 2017 | Sep 30, 2017 |
| 10-Q | Quarterly report | May 3, 2017 | Mar 31, 2017 |
| 10-Q | Quarterly report | Feb 8, 2017 | Dec 31, 2016 |
| 10-Q | Quarterly report | Nov 2, 2016 | Sep 30, 2016 |
| 10-Q | Quarterly report | May 4, 2016 | Mar 31, 2016 |
| 10-Q | Quarterly report | Feb 3, 2016 | Dec 31, 2015 |
| 10-Q | Quarterly report | Nov 4, 2015 | Sep 30, 2015 |
Showing 33 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- In Vitro & In Vivo Diagnostic Substances (SIC 2835)
- Listed as
- MYGN (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Salt Lake City, UT
- SEC filer status
- Accelerated filer
- SEC CIK
- 899923
- Former names
- MYRIAD GENETICS INC (until Nov 5, 2026)
Other In Vitro & In Vivo Diagnostic Substances companies
- Idexx Laboratories Inc /DE IDXX
- Lantheus Holdings, Inc. LNTH
- Neogen Corp NEOG
- Celldex Therapeutics, Inc. CLDX
- Intellia Therapeutics, Inc. NTLA
- QuidelOrtho Corp QDEL
- Achieve Life Sciences, Inc. ACHV
- Alpha Teknova, Inc. TKNO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.